Philogen S.p.A.

Detailed Description

Philogen S.p.A., a biotechnology company, develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company focuses on developing immunocytokines for oncology and in chronic inflammatory diseases. It is developing NIDLEGYTM (DAROMUN), an immunocytokine product used as a neoadjuvant intralesional treatment for melanoma patients with locoregional disease that is in phase III clinical trial for intralesional application and phase II clinical trial to treat non-melanoma skin cancer; FIBROMUN, a human immunomodulatory product consisting of the human anti-EDB antibody L19 to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and DARLEUKIN (L19IL2), a human immunostimulatory product consisting of the human anti-EDB antibody L19, which is in phase II clinical trial for the treatment of metastatic non-small cell lung cancer. The company is also developing DODEKIN, a human immunostimulatory product that comprises vascular targeting antibody fused to the human cytokine interleukin-12 that is in phase I clinical trial to treat advanced solid carcinomas; DEKAVIL (F8IL10), an anti-inflammatory product, which is in phase 2 clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.